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Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder which occurs in one in 3500 male births. 1 It causes progressive skeletal and cardiac muscle degeneration and premature death of the patient. Two major strategies have been investigated for possible treatment of the disease: gene therapy and myoblast transplantation. The first implies direct administration of vectors capable of restoring the missing sarcolemmal protein, dystrophin, in the patient muscles. So far, firstand third-generation adenoviruses seem to be the vectors which yielded the best results for the delivery of either dystrophin minigenes or full-length cDNA. [2] [3] [4] [5] [6] However, one of the problems which has limited the success of gene therapy with these vectors is the immune response raised against those vectors. Humoral and cellular immune reactions led to the rejection of the transduced cells and fibers, probably due to the initial adenoviral capsid load and possibly low level expression of early and late viral antigens which, in turn, are presented by the infected cells. [7] [8] [9] [10] Our research groups have shown that the use of immunosuppressive drugs such as FK506 or monoclonal antibodies against CD4, CD8 and LFA-1 can greatly reduce such reactions and permit sustained transgene expression after adenovirus-mediated gene therapy. [11] [12] [13] Moreover, the use of a new generation adenovirus, that contains either modified or no viral genes, could greatly reduce the immune reactions against the vector-infected cells. 5, 6, [14] [15] [16] Two significant obstacles are still present in the use of direct gene therapy. First, virus-based gene therapy leads to the infection of all cells present at the injection site, including some professional antigen-presenting cells (APC). Upon infection by first-generation viruses, these APCs are known to stimulate the humoral and cellular immune response which, in turn, damage the infected cells and reduce the effectiveness of the viral vectors. 17 Again, new generation adenoviruses which have no viral antigen to present could possibly avoid this obstacle. However, a second problem is that in DMD patients older than 5 years, the absolute number and the regenerating capacity of myoblasts are greatly diminished because of repeated muscle fiber necrosis. 1 Even if all the remaining myoblasts were efficiently transduced, their regenerative capacity might not be sufficient to generate enough muscle to produce an increase in strength. Adenoviral infection of mature post-mitotic muscle fibers has been thought possible for a number of years. 18 However, some studies indicate that this may not always be the case. [19] [20] [21] It thus seems that myoblasts are the main if not the only targets for adenovirus-based gene therapy. Transplantation of genetically modified myoblasts ('ex vivo gene therapy') could, however, be used successfully to bypass both problems by: (1) providing a novel myo-blast pool containing the transgene; and (2) transplanting only myogenic cells already infected and devoid of APC.
Clinical trials have proved to be of only limited success using normal donor myoblast transplantation in DMD patients, even when the donor and host were monozygotic twins. [22] [23] [24] However, in dystrophic immunodeficient mice or immunosuppressed mice, monkeys, and in a few humans having an almost perfectly matched MHC, myoblast transplantation has proven successful. 23, [25] [26] [27] Thus, adequate immunosuppression is of prime importance to control the immune reactions against donor myoblasts. Specific immune responses are triggered not only by incompatible MHC determinants but also by minor antigens present in myoblasts and newly formed myofibers. 28 Without adequate immunosuppression, these cells are thus rejected. Control of this specific immune response may require sustained immunosuppression of DMD patients. However, long-term use of immunosuppressive drugs such as FK506 and cyclosporine has been reported to provoke undesirable side-effects, such as neurotoxicity and nephrotoxicity. 29 By transplanting the host's own cells (autologous transplantation) after in vitro insertion of a functional dystrophin gene, immune rejection could be avoided, thus eliminating the need for long-term use of immunosuppressants. To circumvent the autologous myoblast depletion in DMD patients, such a procedure would have to be carried out in young patients where there are still sufficient myoblasts. The present article reports: (1) the successful transfer of mdx/␤-Gal myoblasts transduced by a first-generation adenovirus carrying a dystrophin minigene expression cassette into immunodeficient SCID mice; and (2) a novel RT-PCRbased technique to quantify human dystrophin minigene expression in vitro and in vivo.
Results
Adenovirus infection of myoblasts Different multiplicities of infection (MOI) ranging from 0.01 to 1000 were tested on cultures of mdx myoblasts. At the highest MOI, a low level of cell toxicity was detected by morphological observation. A rapid augmentation of the PCR product correlating with increasing MOI was observed from MOI 1 to MOI 1000 (Figure 1 ). Under the conditions used, the dystrophin minigene was not detected in non-infected cells or in cells infected with a MOI lower than 1.
Dystrophin minigene expression in culture
To verify the relative expression of mini-Dys mRNA, an RT-PCR was performed on the infected cells. Appreciable levels of mini-Dys mRNA were observed at a high MOI (between 100 and 1000), as revealed by densitometric analysis (Figure 2a and b) . In these cultures, with a MOI of 1000, we found the expression of human mini-Dys to be roughly 20 times higher than mouse dystrophin. As illustrated in Figure 2a , a competitive reaction between mouse and human dystrophin products was observed with increasing MOI. None the less, in the conditions used, a linear augmentation of mouse/human dystrophin ratios versus MOI was still measured (Figure 2b) . A mdx/␤-Gal muscle primary culture was infected as described in Materials and methods and left in normal culture medium until sufficient fusion was observed (roughly 3 days). In these cells, ␤-Gal is under the control of a muscle-specific promoter that is only active after myogenic differentiation. Therefore, only the myotubes or mature myoblasts are ␤-Gal + . As shown in Figure 3a and b, using a MOI of 400, equivalent fusion was obtained in both infected and control cultures, indicating that the adenoviral infection did not noticeably inhibit myoblast differentiation. The cells were then immunostained for dystrophin. As shown in Figure 3d , about 100% of mature myoblasts and myotubes are dys + , while only rare dys + cells could be observed in the uninfected control cells (Figure 3c ). Since the antibody used for this immunofluorescence technique is not human dystrophin specific, these positive cells in the uninfected controls must be revertants.
Dystrophin minigene expression in transplanted muscles
The SCID muscles were transplanted with 1 × 10 6 or 5 × 10 6 infected mdx/␤-Gal cells. Ten days later, the muscles were collected and the total RNA extracted. As shown in Figure 4 , expression of the human mini-Dys is only detected in muscles injected with infected cells. Moreover, a direct correlation between the initial amount of grafted cells and the expression of mini-Dys mRNA 10 days later was observed (compare lanes 3 and 5). Interestingly, we observed that, by transplanting 5 × 10 6 infected cells, comparable amounts of mini-Dys and normal endogenous mouse dystrophin mRNA were obtained ( Figure 4) . To verify the fate of transplanted myoblasts, we immunostained the muscle sections for human dystrophin and compared the results with the sections stained with X-gal 10 days (not shown) and 24 days ( Figure 5 ) after transplantation. Good positional correlation was found between the fibers expressing human dystrophin and those expressing ␤-gal in serial sections. Table 1 summarizes the most relevant parameters observed in all the transplantations. Results were compiled by counting Dys + fibers (Ͼ5 m) in whole sections containing the most ␤-Gal + fibers. Similar numbers of ␤-Gal + fibers were obtained following the transplantation of uninfected myoblasts (data not shown).
Figure 2 Endogenous and transgenic dystrophin expression in mdx myoblasts with increasing MOI. RT-PCR amplification of mouse and human dystrophin (a). Quantification by densitometric analysis of the RT-PCR products following EcoRV digestion (b).

Discussion
The possible toxic effects of long-term use of immunosuppressive drugs such as FK506 or cyclosporine have been well documented. 29 To avoid this possibility, autologous transplantation of genetically modified myoblasts has been proposed and this article describes the initial steps towards this approach. Adenoviral infections can be achieved using high virus-to-cell ratios (MOI) but high MOI have proven toxic to cultured myoblasts or to inhibit differentiation. 18 Thus, a careful balance between high transgene expression and low cell toxicity must be attained. The presence and expression of the human mini-dystrophin transgene was first characterized in cultured mdx myoblasts. Efficient transduction and transgene expression without cell toxicity were observed by PCR and RT-PCR at MOI higher than 100 and lower than 1000. A MOI of 400 was therefore chosen for the infection of myoblasts before their transplantation. Ten days after transplantation, 18% of the muscle fibers were ␤-Gal + and among these, 54% were Dys + . This result correlates more or less with dystrophin expression in cultured myoblasts/myotubes. Indeed, in culture, practically all the observed 'mature myoblasts' and myotubes were Dys + . These muscle sections also contained large regenerating regions in which a high number of small myotubes (Ͻ5 m) were found. Although the exact number of these myotubes is difficult to assess because of their size and the fact that they are found in clusters, the histochemistry clearly shows that they are ␤-Gal + myotubes. A much higher number of ␤-Gal + fibers were found throughout the grafted mouse muscles 24 days after myoblast transplantation (approximately 50% of all fibers), indicating the efficiency of the transplantation and supporting the hypothesis that the regenerating regions observed after 10 days have developed into mature ␤-Gal + muscle fibers. A surprising result was that, although the absolute number of Dys + fibers increased, the Dys + cells/␤-Gal + cell ratio was markedly lower at 24 days than at 10 days after transplantation. Furthermore, as shown previously, the Dys + fiber/␤-Gal + fiber ratio was also lower 10 days after transplantation than in the cultured myoblasts/ myotubes. These results can be explained by the fact that the adenovirus DNA remains episomal, without integrating with the host DNA or replicating itself, whereas the ␤-Gal gene is integrated into the genome of the myoblasts originating from a transgenic animal. When the infected regenerating myoblasts divided in situ, they progressively lost copies of the viral DNA but not of the ␤-Gal gene; thus, the expressed transgene fell below detection level. Some ␤-Gal +
/Dys
+ myoblasts still present in the regenerating regions of the muscle 10 days after transplantation may have divided and lost the Dys transgene before fusing and forming mature fibers during the following 14 days (ie the 24 day result). Ten and 24 days after transplantation, small diameter ␤-Gal + and Dys + fibers were found often close to what seems to be regenerating regions of the muscle, thus indicating recent fiber formation (shown in Figure 5 ). None the less, most of the small ␤-Gal + myotubes found in these regions did not stain positively for dystrophin. These fibers have probably been formed by myoblasts which have divided many times and lost the episomal dystrophin gene. Additionally, some underestimation of the total number of Dys + fibers might have occurred because of the restricted dystrophin nuclear domain. Indeed, our group has shown that, when a myoblast fuses to a preformed fiber and expresses both ␤-Gal and dystrophin, the former protein diffuses further from the point of its translation due to its smaller size and cytosolic localization, thus rendering it detectable on more serial sections of a muscle. 30 For technical reasons, only one cryosection per muscle has been counted. It is therefore possible that a given ␤-Gal + /Dys − fiber in a section is ␤-Gal + /Dys + in another section that is closer to where the myoblast initially fused. Noticeably, we have obtained similar numbers of ␤-Gal + fibers with infected and control myoblasts indicating the low infection-related death of myoblasts.
In our experiments, the immunogenicity of the firstgeneration adenovirus used to infect myoblasts necessitated the transplantation of immunodeficient mice. Moreover, ␤-Gal by itself is known to be immunogenic. In immunocompetent animals, both factors would have induced an immune reaction leading to the rejection of the transduced cells. [7] [8] [9] [10] New generation adenoviral vectors that contain no viral sequences could perhaps enable us, with the same protocol, to transplant immunocompetent animals without sustained immunosuppression. Three elements would further ameliorate the procedure: (1) instead of collecting the patient's myoblasts, one could transform other cell types into myoblasts by co-infecting both MyoD and mini-dystrophin genes; (2) since 90% of the injected cells are thought to die soon after transplantation, 38 ,39 a treatment is needed to increase myoblast survival; and (3) as myoblasts have been shown to remain in close vicinity to the injection sites, increasing myoblast motility immediately after transplantation with appropriate additives to the culture medium could increase their migration. 40 The present work also provides a new and simple way to measure the expression of the mini-Dys transgene in situ. If this procedure was to be used in future human transplantations, the infected myoblasts would have to be tested for fusion efficiency and mini-Dys expression in an animal model. This could be done in SCID mice where human myoblasts have been previously shown to fuse normally with mouse fibers. 41 Until now, immunohistochemistry with a human-specific antibody has been the only method to evaluate human dystrophin expression in a mouse muscle. 41 
Materials and methods
Cell cultures and animals
Muscle biopsies were obtained from mdx/␤-Gal newborn mice (cross between C57 BL10J mdx/mdx mice (Jackson Laboratories, Bar Harbor, ME, USA) and TnILacZ mice). 31 The primary myoblast cultures were obtained using a technique already described. 32 The resulting cells were maintained at 37°C, with 5% CO 2 in M199 medium containing 15% donor calf serum (Gibco BRL), penicillin G (10 000 IU/ml; Gibco BRL) and streptomycin (10 mg/ml; Gibco BRL) for 24 h. The immunodeficient BALB/c SCID mice (2 months old) were obtained from Jackson Laboratories.
Myoblast infection
The ⌬E1-⌬E3 adenoviral vector AdCMV-Dys was produced and purified as described before. 4 A previously frozen adenovirus stock solution of 10 10 p.f.u./ml was used to infect 5 × 10 6 cells at a MOI of 400. Briefly, the cells were rinsed twice in Hank's balanced salt solution (HBSS; Gibco BRL) and were incubated with 2 ml of M199 containing the virus for 2 h at 37°C, 5%CO 2 . They were then rinsed three times in HBSS, harvested by trypsination and further processed for transplantation. Small quantities of cells were replated on LabTek slides (Gibco BRL) and incubated for 2 more days at 37°C for the immunofluorescence technique (see below).
Myoblast transplantation
The left hind legs of the SCID mice were irradiated (20 Gy) 3 days before the transplantation was carried out. As described earlier, this dose of irradiation inhibits the proliferation of the host myoblasts. 33, 34 The day before transplantation, the left tibialis anterior muscle (TA) was surgically exposed and 7 l of notexin (5 g/ml) were injected into several sites in the muscle to induce fiber necrosis. 35 On the day of transplantation, the infected cells (2.5 × 10 6 for the immunohistochemistry experiment, 1 and 5 × 10 6 for the RT-PCR experiment) were collected, pelleted and resuspended in approximately 15 l of HBSS. This volume was then injected into multiple sites in the left TA. Cell viability was assessed by trypan blue staining.
Muscle removal and preparation
Ten or 24 days after transplantation, the mice were deeply anesthetized and perfused using a 0.9% sodium chloride, 2 IU/ml heparin solution. The grafted and contralateral TA were then removed and immersed overnight in a 30% sucrose solution at 4°C. Muscles were embedded in Cryomatrix compound (Shandon, Pittsburg, PA, USA), frozen in liquid nitrogen and cryosectioned at 10 and 30 m.
␤-Gal histochemistry
The 30 m muscle sections and cells in culture were fixed with 0.25% glutaraldehyde in PBS. They were then rinsed three times with PBS. ␤-Gal expression was revealed with overnight incubation in a 0.4 mm X-gal (Boehringer Mannheim, Laval, Qc, Canada), 3 mm potassium ferrocyanide, 3 mm potassium ferricyanide, 100 m magnesium chloride and PBS solution.
Dystrophin immunochemistry and immunofluorescence
Human dystrophin minigene (mini-Dys) expression was detected on 10 m sections by an immunoperoxidase technique using the NCLDys3 monoclonal antibody. 36 The secondary antibody was a rabbit anti-mouse coupled to peroxidase (Dako, Mississauga, Ont, Canada). The peroxidase activity was revealed with diaminobenzidine (0.25 mg/ml) and hydrogen peroxide (0.015%). To detect dystrophin in myoblasts and myotubes in culture, we used a polyclonal rabbit anti-dystrophin that recognizes the C-terminal part of all the mammalian dystrophins (dilution 1:750; generous gift from Dr JS Chamberlain, University of Michigan). The secondary antibody was in that case an anti-rabbit coupled to FITC (dilution 1/40; Dako).
RT-PCR detection of dystrophin minigene mRNA
The expression of mini-Dys mRNA in culture and in the transplanted muscles was detected by reverse transcriptase RT-PCR. In culture, the cells were lysed and the total RNA was directly isolated in TRIZol (Gibco BRL, Burlington, Ont, Canada). For use of the muscles, the mice were deeply anesthetized and perfused briefly with the sodium chloride/heparin solution. The muscles were then removed and immediately frozen in liquid nitrogen. Total RNA was extracted with TRIZol and treated with DNAse (Gibco BRL). A primer set was made to amplify both human and mouse dystrophin fragments under the same conditions. The 5′ primer (5′-CCAAACTA-GAAATGCCATCTTC-3′) corresponds to nucleotides 7578 to 7599 of the normal human dystrophin cDNA (GenBank accession No. M18533, M17154, M18026) and 7569 to 7590 of mouse dystrophin cDNA (GenBank accession No. M68859). The 3′ primer (5′-TCTGAATTCTTTCAATTCGAT-3′) corresponds to nucleotides 7863 to 7883 in the normal human dystrophin cDNA and 7854 to 7874 in the mouse dystrophin cDNA. To distinguish the mouse and human RT-PCR products, an EcoRV digestion was performed yielding two fragments of 145 and 160 bp for human mini-dystrophin and 305 bp for mouse dystrophin. 200 ng of DNAse-treated RNA was first reverse-transcribed by MoMLV RT and further amplified by Tth polymerase (33 cycles; Boehringer Mannheim).
PCR-mediated evaluation of adenovirus infection
Mdx myoblasts were infected with the adenoviral vector (Ad-CMV-Dys) at different MOI ranging from 0.01 to 1000. Two days after the infection, DNA was extracted by a 1 h incubation at 37°C in a lysing solution (50 mm Tris-HCl pH 8.0, 20 mm EDTA, 1% SDS, 0.48 mg/ml proteinase K (Boehringer Mannheim)), followed by phenolchloroform extraction and ethanol precipitation. To amplify the mini-dystrophin DNA, a 5′ primer (5′-GAGTA-CAGCACAGGAAACTG-3′) corresponding to the junction between exons 16 (nucleotide 2188) and 49 (nucleotide 7324) of normal dystrophin 37 was designed. This junctional sequence is therefore only present in mini-dystrophin cDNA and mRNA. The 3′ primer (5′-AGCAGGTACCTCCAACATCAAG-3′) corresponds to nucleotides 7600 to 7621 in the normal human dystrophin cDNA. 200 ng of DNA was amplified using Tth polymerase.
